ArticleNeurology and therapy2026

Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial.

Lei Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.